Who
Dan Benjamin Teleman
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Nasus Pharma.
In numbers
- Trades disclosed
- 6
- Buys
- 3
- Sells
- 0
- Bought
- $124K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 31 Mar 2026
- Last trade
- 17 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
1 Mar – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 22 Jun 2026 | NSRX Nasus PharmaBiotechnology | SEC FORM 4 Bought | $20K6,550 at $3.10 | filing |
| 17 Jun 2026filed 22 Jun 2026 | NSRX Nasus PharmaBiotechnology | SEC FORM 4 Bought | $20K6,550 at $3.10 | filing |
| 22 Apr 2026filed 22 Apr 2026 | NSRX Nasus PharmaBiotechnology | SEC FORM 4 Bought | $11K2,900 at $3.76 | filing |
| 22 Apr 2026filed 22 Apr 2026 | NSRX Nasus PharmaBiotechnology | SEC FORM 4 Bought | $11K2,900 at $3.76 | filing |
| 31 Mar 2026filed 1 Apr 2026 | NSRX Nasus PharmaBiotechnology | SEC FORM 4 Bought | $31K15,000 at $2.04 | filing |
| 31 Mar 2026filed 1 Apr 2026 | NSRX Nasus PharmaBiotechnology | SEC FORM 4 Bought | $31K15,000 at $2.04 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
Related people
Nobody else traded the same names lately.